Breaking News Instant updates and real-time market news.

SSNLF

Samsung

, BIIB

Biogen

$280.57

1.97 (0.71%)

07:33
06/23/17
06/23
07:33
06/23/17
07:33

Samsung Bioepis' Imrali recommended for approval by EMA

Samsung Bioepis announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion on Imraldi, a biosimilar candidate referencing Humira, for rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa, Crohn's disease, pediatric Crohn's disease, ulcerative colitis and uveitis. The CHMP's positive opinion will now be referred to the European Commission which will review and decide on the grant of a marketing authorization for Imraldi. If a marketing authorization is granted by the EC, Imraldi will be commercialized in the European Union by Biogen (BIIB). Humira is a registered trademark of AbbVie (ABBV). Samsung Bioepis is a JV between Samsung (SSNLF) and Biogen.

SSNLF

Samsung

BIIB

Biogen

$280.57

1.97 (0.71%)

ABBV

AbbVie

$73.18

1.84 (2.58%)

  • 25

    Jul

SSNLF Samsung

05/17/17
MSCO
05/17/17
NO CHANGE
Target $177
MSCO
Overweight
Apple target raised to $177 at Morgan Stanley after survey shows rising loyalty
Morgan Stanley analyst Katy Huberty reported that the firm's recent survey of 1,000 U.S. consumers shows a rising iPhone retention rate, with 92% of iPhone owners who see upgrading their phone in the next 12 months saying they plan to stick to an iPhone, up from the 86% retention rate in last year's survey. Apple's (AAPL) 92% loyalty rate "dwarfs" that of all other vendors, with its biggest competitor, Samsung (SSNLF), seeing a 77% retention rate, she noted. Huberty, who sees Apple being positioned to gain increasing U.S. smartphone share, raised her price target on Apple to $177 from $161 and keeps an Overweight rating on the stock.
04/28/17
CHLM
04/28/17
NO CHANGE
Target $120
CHLM
Buy
Skyworks price target raised to $120 from $110 at Craig-Hallum
Craig-Hallum analyst Anthony Stoss raised his price target for Skyworks (SWKS) to $120 from $110 after the company reported results and guidance above estimates driven by content expansion in Samsung's (SSNLF) Galaxy S8 and at Huawei, and continued strength in its Internet of Things business. The analyst reiterates a Buy rating on the shares.
04/28/17
NEED
04/28/17
NO CHANGE
Target $108
NEED
Buy
Skyworks price target raised to $108 from $92 at Needham
Needham analyst N. Quinn Bolton raised his price target for Skyworks (SWKS) to $108 from $92 after the company delivered another beat and raise quarter driven by content gains at Huawei and Samsung (SSNLF) and issued a strong outlook for the rest of 2017. The analyst reiterates a Buy rating on the Skyworks' shares.
04/05/17
CHLM
04/05/17
NO CHANGE
Target $18
CHLM
Buy
STMicroelectronics to benefit from content jump in iPhone 8, says Craig-Hallum
Craig-Hallum analyst Anthony Stoss raised his STMicroelectronics' (STM) March and June quarter estimates to account for content increases in Samsung's (SSNLF) Galaxy S8 and Apple's (AAPL) iPhone 8, coupled with continued strong demand for the Nintendo (NTDOY) Switch and strength in the company's connected car business. The analyst says STMicroelectronics remains one of his top names in 2017 and would be a buyer heading into both the S8 and iPhone 8 launches. He reiterates a Buy rating and $18 price target on STMicroelectronics' shares.
BIIB Biogen
$280.57

1.97 (0.71%)

06/19/17
UBSW
06/19/17
UPGRADE
Target $270
UBSW
Neutral
Biogen upgraded to Neutral from Sell at UBS
UBS analyst Carter Gould upgraded Biogen to Neutral and raised his price target for the shares to $270 from $262. The biotech closed Friday down $3.28 from $251.74. The analyst sees an improved risk/reward and a positive near-term setup going into the Q2 earnings call and strategic review. The competitive threat to Biogen's Spinraza from gene therapy is now priced into the shares and sentiment is near a bottom, Gould tells investors in a research note. The analyst is also "incrementally more constructive" on aducanumab. Gould thinks the stock's underperformance "stops here."
06/19/17
06/19/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Biogen (BIIB) upgraded to Neutral from Sell at UBS with analyst Carter Gould saying he sees an improved risk/reward and a positive near-term setup going into the second quarter earnings call and strategic review. 2. Clovis (CLVS) upgraded to Neutral from Sell at Chardan. 3. Cedar Fair (FUN) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Christopher Prykull saying early season indicators appear strong as several management teams noted ongoing leisure strength at the firm's Lodging, Gaming Restaurant and Leisure Conference. 4. Athene Holding (ATH) upgraded to Outperform from Neutral at Credit Suisse with analyst John Nadel saying he believes the probability is increasing that Athene will use acquisitions to accelerate its balance sheet and earnings growth. 5. Credit Suisse (CS) upgraded to Buy from Hold at Deutsche Bank with analyst Kinner Lakhani saying an inflection in the company's operating results is near following the recent anticipated capital raise. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/22/17
LEER
06/22/17
NO CHANGE
LEER
Leerink sees reasons for biotech rally to continue
Leerink analyst Geoffrey Porges attributes the recent strength in the biotech sector to a lessening of the perceived fears of pricing regulations and a favorable tone from the FDA. However, he believes the sector could advance at least 15% more, as he foresees more positive operating results and still expects more industry consolidation. Among large cap biotech names, Porges maintains Outperform ratings on Regeneron (REGN), Celgene (CELG), Vertex (VRTX) and Alexion(ALXN) and keeps Market Perform ratings on AbbVie (ABBV), Amgen (AMGN), Gilead (GILD) and Biogen (BIIB).
06/23/17
DBAB
06/23/17
INITIATION
Target $315
DBAB
Buy
Biogen initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Andrew Peters started Biogen with a Buy rating and $315 price target, as he sees meaningful top-line growth driven by the pipeline and recently approved products and also expects margin expansion. Peters also hold a favorable view on Biogen's pipeline optionality, he tells investors.
ABBV AbbVie
$73.18

1.84 (2.58%)

06/22/17
SOCG
06/22/17
UPGRADE
SOCG
Buy
AbbVie upgraded to Buy from Hold at Societe Generale
06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
AbbVie should be bought on weakness, says SunTrust
SunTrust analyst John Boris says that AbbVie should be bought on weakness after the USPTO invalidated two of the company's patents for Humira. The analyst says that the ruling "makes a small dent" in the company's IP for Humira, as he notes that the company has more than 100 patents for the drug. He thinks that Humira biosimilars will enter the market later than the Street expects. Boris, maintaining that the company has over a dozen pipeline catalysts this year, recommends buying the shares on weakness.
06/12/17
LEER
06/12/17
NO CHANGE
Target $90
LEER
Outperform
Eli Lilly price target lowered to $90 from $93 at Leerink
Leerink analyst Seamus Fernandez lowered his price target for Eli Lilly (LLY) to $90 to reflect reduced sales forecasts for baricitinib, an oral JAK1/2 inhibitor to treat rheumatoid arthritis which the company collaborates with Incyte (INCY). Following AbbVie's (ABBV) positive Phase 3 data last week for its JAK1 inhibitor upadacitinib, Fernandez dropped his U.S. peak sales estimate for baricitinib by more than 50% to $400M and pushed out his U.S. launch time to 2020 from 2018. The analyst keeps an Outperform rating on Lilly shares.

TODAY'S FREE FLY STORIES

CELC

Celcuity

20:34
09/19/17
09/19
20:34
09/19/17
20:34
Syndicate
Celcuity 2.4M share IPO priced at $9.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

BSTI

BEST Inc

20:33
09/19/17
09/19
20:33
09/19/17
20:33
Syndicate
Best Inc 45M share IPO priced at $10.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

GIS

General Mills

$55.38

-1.05 (-1.86%)

20:25
09/19/17
09/19
20:25
09/19/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

PCRX

Pacira

$35.70

-0.6 (-1.65%)

20:00
09/19/17
09/19
20:00
09/19/17
20:00
Recommendations
Pacira analyst commentary  »

Pacira's Exparel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AVEVF

Aveva

19:56
09/19/17
09/19
19:56
09/19/17
19:56
Upgrade
Aveva rating change  »

Aveva upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZLAB

Zai Lab

18:58
09/19/17
09/19
18:58
09/19/17
18:58
Syndicate
Zai Lab announces upsizing of U.S. IPO of American depositary shares »

Zai Lab announces its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

OHI

Omega Healthcare

$32.53

-0.12 (-0.37%)

18:30
09/19/17
09/19
18:30
09/19/17
18:30
Hot Stocks
Omega Healthcare provides hurricane update »

Omega Healthcare provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

F

Ford

$11.72

0.09 (0.77%)

18:30
09/19/17
09/19
18:30
09/19/17
18:30
Periodicals
Ford to slash production at five North American assembly plants, Reuters says »

Ford announced it intends…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 26

    Oct

FDX

FedEx

$216.00

0.92 (0.43%)

18:26
09/19/17
09/19
18:26
09/19/17
18:26
Hot Stocks
FedEx says without cyberattack FY18 guidance would not have changed »

Comments are from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

EE

El Paso Electric

$54.85

0.05 (0.09%)

18:25
09/19/17
09/19
18:25
09/19/17
18:25
Hot Stocks
El Paso Electric announces City of El Paso approved settlement terms »

El Paso Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

18:17
09/19/17
09/19
18:17
09/19/17
18:17
Hot Stocks
Bed Bath & Beyond says biggest component in drop of FY17 EPS view is operations »

Company dropped its FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

CPRT

Copart

$32.54

-0.32 (-0.97%)

18:11
09/19/17
09/19
18:11
09/19/17
18:11
Earnings
Copart reports Q4 EPS 30c, consensus 29c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

STLD

Steel Dynamics

$33.83

0.03 (0.09%)

18:04
09/19/17
09/19
18:04
09/19/17
18:04
Earnings
Steel Dynamics sees Q3 adjusted EPS 63c-67c, consensus 70c »

Steel Dynamics provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XBKS

Xenith Bankshares

$29.96

0.42 (1.42%)

17:58
09/19/17
09/19
17:58
09/19/17
17:58
Hot Stocks
Treasury exits stake in Xenith Bankshares »

Xenith Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$62.93

0.23 (0.37%)

17:54
09/19/17
09/19
17:54
09/19/17
17:54
Periodicals
Breaking Periodicals news story on Bristol-Myers »

Times:NHS will supply…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 18

    Oct

  • 26

    Oct

  • 09

    Nov

  • 05

    Mar

BBBY

Bed Bath & Beyond

17:54
09/19/17
09/19
17:54
09/19/17
17:54
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

DESP

Despegar.com

17:52
09/19/17
09/19
17:52
09/19/17
17:52
Syndicate
Despegar.com 12.7M share IPO priced at $26.00 »

The IPO priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

WAC

Walter Investment

$0.65

0.186 (40.09%)

17:50
09/19/17
09/19
17:50
09/19/17
17:50
Hot Stocks
Walter Investment says Barclays to increase financing available »

On September 13, Walter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBAY

CymaBay

17:49
09/19/17
09/19
17:49
09/19/17
17:49
Initiation
CymaBay initiated at Cantor »

CymaBay initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

BBBY

Bed Bath & Beyond

17:46
09/19/17
09/19
17:46
09/19/17
17:46
Hot Stocks
Bed Bath & Beyond sees net drop in Bed Bath & Beyond stores in FY17 »

Says rate of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

EVH

Evolent Health

$15.65

-0.8 (-4.86%)

17:45
09/19/17
09/19
17:45
09/19/17
17:45
Initiation
Evolent Health initiated at KeyBanc »

Evolent Health initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

BPL

Buckeye Partners

$56.33

0.64 (1.15%)

17:44
09/19/17
09/19
17:44
09/19/17
17:44
Syndicate
Buckeye Partners announces $210M in limited partnership unit sales »

Buckeye Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RL

Ralph Lauren

$91.03

0.87 (0.96%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43
Initiation
Ralph Lauren initiated at Barclays »

Ralph Lauren initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

PVH

PVH Corp.

$127.47

-0.54 (-0.42%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43
Initiation
PVH Corp. initiated at Barclays »

PVH Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

, ORIG

Ocean Rig UDW

$0.16

-0.0083 (-4.90%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Gemphire…

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

ORIG

Ocean Rig UDW

$0.16

-0.0083 (-4.90%)

IOVA

Iovance Biotherapeutics

$8.55

0.3 (3.64%)

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

FDX

FedEx

$216.00

0.92 (0.43%)

ADBE

Adobe

$156.60

0.83 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

  • 25

    Sep

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.